These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 38780840)
21. Efficacy and safety of PD-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer. Li L; Xu C; Wang W; Zhang Q Clin Respir J; 2024 May; 18(5):e13763. PubMed ID: 38717297 [TBL] [Abstract][Full Text] [Related]
22. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC. Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972 [TBL] [Abstract][Full Text] [Related]
23. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials. Shi Y; Duan J; Guan Q; Xue P; Zheng Y Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922 [TBL] [Abstract][Full Text] [Related]
24. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials. Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874 [TBL] [Abstract][Full Text] [Related]
25. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors. Song P; Zhang J; Shang C; Zhang L Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891 [TBL] [Abstract][Full Text] [Related]
26. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830 [TBL] [Abstract][Full Text] [Related]
27. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. Yang Y; Luo H; Zheng XL; Ge H Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of temozolomide combined with whole brain radiotherapy for non-small cell lung cancer brain metastases. Zhu Y; Fu L; Jing W; Guo D; Kong L; Yu J Thorac Cancer; 2018 Sep; 9(9):1121-1128. PubMed ID: 29947170 [TBL] [Abstract][Full Text] [Related]
29. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224 [TBL] [Abstract][Full Text] [Related]
30. Combination of radiation therapy for brain metastasis and anti-PD-1/PD-L1 treatment in non-small cell lung cancer: two cases and review of the literature. Nigro O; Tuzi A; Coppola A; Tartaro T; Chini C; Pinotti G Anticancer Drugs; 2021 Apr; 32(4):460-464. PubMed ID: 33587349 [TBL] [Abstract][Full Text] [Related]
31. Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study. Higaki H; Nishioka K; Otsuka M; Nishikawa N; Shido M; Minatogawa H; Nishikawa Y; Takashina R; Hashimoto T; Katoh N; Taguchi H; Kinoshita R; Yasuda K; Mori T; Uchinami Y; Koizumi F; Fujita Y; Takahashi S; Hattori T; Nishiyama N; Aoyama H Radiat Oncol; 2023 Feb; 18(1):25. PubMed ID: 36750899 [TBL] [Abstract][Full Text] [Related]
32. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442 [TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248 [TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer. Xu X; Huang Z; Zheng L; Fan Y Int J Cancer; 2018 Jun; 142(11):2344-2354. PubMed ID: 29318609 [TBL] [Abstract][Full Text] [Related]
35. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome. Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T Front Immunol; 2021; 12():651086. PubMed ID: 34248939 [TBL] [Abstract][Full Text] [Related]
36. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China. Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361 [TBL] [Abstract][Full Text] [Related]
37. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? Zhang Y; Zhou H; Zhang L J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312 [TBL] [Abstract][Full Text] [Related]
38. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer. Wang C; Yu X; Wang W Medicine (Baltimore); 2016 Dec; 95(52):e5539. PubMed ID: 28033249 [TBL] [Abstract][Full Text] [Related]
39. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis. Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822 [TBL] [Abstract][Full Text] [Related]
40. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]